Price Action to Note: After Today’s Significant Increase, Is Aratana Therapeutics Inc’s Near-Term Analysis Positive?

Price Action to Note: After Today's Significant Increase, Is Aratana Therapeutics Inc's Near Term Analysis Positive?

The stock of Aratana Therapeutics Inc (NASDAQ:PETX) is a huge mover today! The stock increased 5.05% or $0.45 during the last trading session, hitting $9.36. About 842,982 shares traded hands or 19.52% up from the average. Aratana Therapeutics Inc (NASDAQ:PETX) has risen 165.97% since February 26, 2016 and is uptrending. It has outperformed by 155.55% the S&P500.
The move comes after 9 months positive chart setup for the $314.55M company. It was reported on Oct, 1 by We have $16.85 PT which if reached, will make NASDAQ:PETX worth $251.64M more.

Analysts await Aratana Therapeutics Inc (NASDAQ:PETX) to report earnings on November, 3. They expect $-0.44 earnings per share, down 37.50% or $0.12 from last year’s $-0.32 per share. After $0.69 actual earnings per share reported by Aratana Therapeutics Inc for the previous quarter, Wall Street now forecasts -163.77% negative EPS growth.

Aratana Therapeutics Inc (NASDAQ:PETX) Ratings Coverage

Out of 6 analysts covering Aratana Therapeutics (NASDAQ:PETX), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Aratana Therapeutics has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of Aratana Therapeutics Inc (NASDAQ:PETX) has “Buy” rating given on Wednesday, July 29 by Lake Street. The rating was maintained by Stifel Nicolaus on Wednesday, March 16 with “Buy”. Jefferies initiated the shares of PETX in a report on Friday, August 19 with “Buy” rating. The firm has “Hold” rating by Craig Hallum given on Friday, September 25. The stock of Aratana Therapeutics Inc (NASDAQ:PETX) earned “Overweight” rating by Barclays Capital on Thursday, August 11. Credit Suisse initiated Aratana Therapeutics Inc (NASDAQ:PETX) on Thursday, February 4 with “Outperform” rating.

According to Zacks Investment Research, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.”

Insitutional Activity: The institutional sentiment increased to 1.59 in 2016 Q2. Its up 0.47, from 1.12 in 2016Q1. The ratio increased, as 11 funds sold all Aratana Therapeutics Inc shares owned while 21 reduced positions. 12 funds bought stakes while 39 increased positions. They now own 30.25 million shares or 0.77% less from 30.49 million shares in 2016Q1.
The New York-based Morgan Stanley has invested 0% in Aratana Therapeutics Inc (NASDAQ:PETX). The Texas-based Dimensional Fund Lp has invested 0% in Aratana Therapeutics Inc (NASDAQ:PETX). The Pennsylvania-based Pnc Services Grp has invested 0% in Aratana Therapeutics Inc (NASDAQ:PETX). Barclays Public Limited Liability holds 0% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX) for 482 shares. Kcg Inc, a New Jersey-based fund reported 34,726 shares. State Street holds 0% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX) for 600,355 shares. Credit Suisse Ag accumulated 26,755 shares or 0% of the stock. Citigroup Inc has 0% invested in the company for 6,637 shares. Wellington Mngmt Grp Ltd Liability Partnership accumulated 0% or 1.15 million shares. Moreover, Alpinvest Bv has 1.25% invested in Aratana Therapeutics Inc (NASDAQ:PETX) for 100,001 shares. Blackrock Fund accumulated 1.31 million shares or 0% of the stock. Moreover, Commercial Bank Of America De has 0% invested in Aratana Therapeutics Inc (NASDAQ:PETX) for 6,667 shares. Moreover, Voya Lc has 0% invested in Aratana Therapeutics Inc (NASDAQ:PETX) for 15,920 shares. Citadel Advisors Ltd Com holds 44,199 shares or 0% of its portfolio. Price T Rowe Inc Md last reported 102,601 shares in the company.

Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 4 selling transactions for $1.47 million net activity. St Peter Steven had sold 50,000 shares worth $462,500. The insider TOOMAN CRAIG A sold 30,000 shares worth $277,599. On Friday, June 10 HEINEN ERNST sold $100,862 worth of the stock or 15,000 shares.

More notable recent Aratana Therapeutics Inc (NASDAQ:PETX) news were published by: which released: “How Aratana Therapeutics Inc. Clawed Its Way to a 17% Gain in August” on September 09, 2016, also with their article: “Why Aratana Therapeutics Inc. Shares Crashed Today” published on September 25, 2015, published: “Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome …” on June 30, 2016. More interesting news about Aratana Therapeutics Inc (NASDAQ:PETX) were released by: and their article: “Aratana Therapeutics Reports First Quarter 2016 Financial Results” published on May 05, 2016 as well as‘s news article titled: “Aratana Therapeutics Files for Second FDA Approval” with publication date: March 22, 2016.

PETX Company Profile

Aratana Therapeutics, Inc., incorporated on December 1, 2010, is a pet therapeutics firm focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. The Company’s lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). The Company’s product candidates also include AT-014 for dogs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment